These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
893 related articles for article (PubMed ID: 30416077)
1. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077 [TBL] [Abstract][Full Text] [Related]
2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729 [TBL] [Abstract][Full Text] [Related]
3. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114 [TBL] [Abstract][Full Text] [Related]
4. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3. Boorjian S Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671 [TBL] [Abstract][Full Text] [Related]
5. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ; Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406 [TBL] [Abstract][Full Text] [Related]
6. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480 [TBL] [Abstract][Full Text] [Related]
7. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295 [TBL] [Abstract][Full Text] [Related]
8. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394 [TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983 [TBL] [Abstract][Full Text] [Related]
10. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128 [TBL] [Abstract][Full Text] [Related]
11. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218 [TBL] [Abstract][Full Text] [Related]
12. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076 [TBL] [Abstract][Full Text] [Related]
13. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor. Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695 [TBL] [Abstract][Full Text] [Related]
15. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773 [TBL] [Abstract][Full Text] [Related]
16. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860 [TBL] [Abstract][Full Text] [Related]
17. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446 [TBL] [Abstract][Full Text] [Related]
18. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967 [TBL] [Abstract][Full Text] [Related]
19. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Ibragimova I; Maradeo ME; Dulaimi E; Cairns P Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518 [TBL] [Abstract][Full Text] [Related]